![](https://library.celltelligence.com/wp-content/uploads/2020/12/ASH-2020-Autolus.png)
$0
Autolus’s Industrialized Manufacturing Process for Obe-cel; Updated Results From Autolus’s Ph1 ALLCAR19 and Ph1 CARPALL Trials; ASH 2021 Day 3 Autolus Investor Event
On Monday, December 13, Autolus held their investor event (press release / presentation) comparing obe-cel’s (CD19 CAR-T; formerly AUTO1) Ph1 ALLCAR19 study and Ph1b/2 FELIX trial in r/r B-ALL. Moreover, management provided updated preclinical and clinical data for obe-cel’s ALLCAR19 iNHL cohort and AUTO1/22 (CD19 x CD22 CAR-T) in r/r pediatric ALL. Below, Celltelligence provides insights on obe-cel’s industrialized manufacturing process, while discussing Autolus’s AUTO1/22 indication strategy.